Skin manifestations associated with checkpoint inhibitors
Abstract Immune checkpoint inhibitors (ICIs) are a relatively novel class of drugs whose administration has been approved for several malignancies. Adverse events are quite common, and the skin is the most frequently involved organ. In fact, regardless of the neoplasm being treated, more than 50% of...
Main Authors: | Gianluca Nazzaro, Stefano Buffon, Serena Giacalone, Carlo Alberto Maronese, Angelo Valerio Marzano |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-06-01
|
Series: | JEADV Clinical Practice |
Subjects: | |
Online Access: | https://doi.org/10.1002/jvc2.27 |
Similar Items
-
Clinical Diagnosis and Treatment Recommendations for the Pneumonitis Associated with Immune Checkpoint Inhibitor
by: Hanping WANG, et al.
Published: (2019-10-01) -
Neurologic Toxicity of Immune Checkpoint Inhibitors: A Review of Literature
by: Víctor Albarrán, et al.
Published: (2022-02-01) -
Management of Dermatologic Toxicities Related to Immune Checkpoint Inhibitors
by: Xiaoyan SI, et al.
Published: (2019-10-01) -
Patterns of immune-related adverse events in patients treated with immune checkpoint inhibitors: a Brazilian real-world analysis
by: Maria Paula Furtado Santos, et al.
Published: (2022-12-01) -
Management of immune checkpoint inhibitor‐related adverse events: A review of case reports
by: Xiaoyan Si, et al.
Published: (2020-03-01)